Sofosbuvir for treatment of chronic hepatitis C

详细信息    查看全文

• 作者：Sarah Kattakuzhy (2)
  Rachel Levy (1)
  Shyam Kottilil (1) (2)
  
  2. Division of Infectious Diseases ; Institute of Human Virology ; University of Maryland School of Medicine ; Baltimore ; MD ; USA
  1. Immunopathogenesis Section ; Laboratory of Immunoregulation ; National Institute of Allergy and Infectious Diseases ; National Institutes of Health ; Bldg 10 ; Rm. 11N204 ; Bethesda ; MD ; 20892 ; USA
  
• 关键词：Hepatitis C ; Direct ; acting antiviral therapy ; Interferon free
• 刊名：Hepatology International
• 出版年：2015
• 出版时间：April 2015
• 年：2015
• 卷：9
• 期：2
• 页码：161-173
• 全文大小：541 KB
• 参考文献：1. Lam, AM, Espiritu, C, Bansal, S (2013) Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother 56: pp. 3359-3368 28/AAC.00054-12" target="_blank" title="It opens in new window">CrossRef
  2. Klein R, Struble K. Approval of Sovaldi (sofosbuvir) tablets for the treatment of chronic hepatitis C. Federal Drug Administration 2013, Published 6 Dec 2013. 20.htm" class="a-plus-plus">http://www.fda.gov/ForPatients/Illness/HepatitisBC/ucm377920.htm
  3. Sofia, MJ, Bao, D, Chang, W (2010) Discovery of a 尾-d-2鈥?deoxy-2鈥?伪-fluoro-2鈥?尾-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem 53: pp. 7202-7218 21/jm100863x" target="_blank" title="It opens in new window">CrossRef
  4. Murakami, E, Tolstykh, T, Bao, H (2010) Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J Biol Chem 285: pp. 34337-34347 2" target="_blank" title="It opens in new window">CrossRef
  5. Rodriguez-Torres, M, Lawitz, E, Kowdley, KV (2013) Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-na茂ve patients with HCV genotype-1: a randomized, 28-day, dose-ranging trial. J Hepatol 58: pp. 663-668 2012.11.018" target="_blank" title="It opens in new window">CrossRef
  6. Lam, AM, Espiritu, C, Bansal, S (2012) Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother 56: pp. 3359-3368 28/AAC.00054-12" target="_blank" title="It opens in new window">CrossRef
  7. Denning, J, Cornpropst, M, Flach, SD (2013) Pharmacokinetics, safety, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor for hepatitis C virus, following single ascending doses in healthy subjects. Antimicrob Agents Chemother 57: pp. 1201-1208 28/AAC.01262-12" target="_blank" title="It opens in new window">CrossRef
  8. Kirby B. Population pharmacokinetics of sofosbuvir and its major metabolite (GS-331007) in healthy and HCV-infected adult subjects. / 64th Annual Meeting of the American Association for the Study of Liver Diseases 2013, Washington, DC. Nov 1鈥?, Abstract 69
  9. Cornpropst, MT, Denning, J, Clemons, D (2012) The effect of renal impairment and end stage renal disease on the single dose pharmacokinetics of PSI-7977. J Hepatol 56: pp. S433 278(12)61113-1" target="_blank" title="It opens in new window">CrossRef
  10. Kirby B. GS-7977 & HIV ARTs PK鈥攏o clinically significant pharmacokinetic interactions between sofosbuvir (GS-7977) and HIV antiretrovirals atripla, rilpivirine, darunavir/ritonavir, or raltegravir in healthy volunteers. / 63rd Annual Meeting of the American Association for the聽 / Study of Liver Diseases 2012, Boston, MA. Nov 9鈥?2, Abstract 1877
  11. Kowdley, KV, Hassanein, T, Gane, EJ (2013) 842 sofosbuvir safety and tolerability in 741 patients treated for up to 24 weeks. J Hepatol 58: pp. s345 278(13)60844-2" target="_blank" title="It opens in new window">CrossRef
  12. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated hcv genotype-1 infection. N Engl J Med. 2014;370(20):1889鈥?898
  13. Afdhal, N, Reddy, KR, Nelson, DR (2014) Ledipasvir and sofosbuvir for previously treated HCV genotype-1 infection. N Engl J Med 370: pp. 1483-1493 CrossRef
  14. Kowdley, KV, Gordon, SC, Reddy, KR (2014) Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 370: pp. 1879-1888 2355" target="_blank" title="It opens in new window">CrossRef
  15. Lawitz, E, Poordad, FF, Pang, PS (2014) Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype-1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 383: pp. 515-523 2121-2" target="_blank" title="It opens in new window">CrossRef
  16. Sulkowski, MS, Gardiner, DF, Rodriguez-Torres, M (2014) Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 370: pp. 211-221 218" target="_blank" title="It opens in new window">CrossRef
  17. Xu S. Sofosbuvir selects the NS5B S282T mutation in vitro in genotype-1鈥? replicons and is not cross-resistant to resistance-associated variants selected by other classes of antiviral inhibitors. / 64th Annual Meeting of the American Association for the Study of Liver Diseases 2013, Washington, DC. Nov 1鈥?
  18. Svarovskaia, E, Dvory-Sobol, H, Gontcharova, V (2013) No s282t mutation detected by deep sequencing in a large number of HCV patients who received GS-7977 with RBV and/or GS-0938: the QUANTUM study. J Hepatol 58: pp. S496 278(13)61222-2" target="_blank" title="It opens in new window">CrossRef
  19. Gane, EJ, Stedman, CA, Hyland, RH (2013) Nucleotide polymerase inhibitor Sofosbuvir plus Ribavirin for Hepatitis C. N Engl J Med 368: pp. 34-44 208953" target="_blank" title="It opens in new window">CrossRef
  20. Nelson DR, Lalezari J, Lawitz E, et al. Once daily PSI-7977 plus Peg-IFN/RBV in HCV GT1: 98% rapid virologic response, complete early virologic response: the PROTON study. / 46th Annual Meeting of the European Association for the Study of the Liver / (EASL) 2011, Berlin. March 30鈥揂pril 3, Abstract 9
  21. Lawitz E, Rodriguez-Torres M, Denning J, et al. Once daily dual-nucleotide combination of PSI-938 and PSI-7977 provides 94% HCV RNA < load at day 14: first purine/pyrimidine clinical combination data (the NUCLEAR study). / 46th Annual Meeting of the European Association for the Study of the Liver (EASL) 2011, Berlin. March 30鈥揂pril 3, Abstract 8
  22. Kowdley, KV, Lawitz, E, Crespo, I (2013) Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 381: pp. 2100-2107 247-0" target="_blank" title="It opens in new window">CrossRef
  23. Lawitz, E, Lalezari, JP, Hassanein, T (2013) Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 13: pp. 401-408 CrossRef
  24. Chen, J, Florian, J, Carter, W, Fleishcer, RD, Hammerstrom, TS (2013) Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 144: pp. 1450-1455 2013.02.039" target="_blank" title="It opens in new window">CrossRef
  25. Zeuzem, S, Mensa, FJ (2013) Concordance between sustained virologic response week 12 (SVR12) and SVR24 in genotype 1 hepatitis C virus patients receiving interferon-free treatment in the SOUND-C2 study. Hepatology 58: pp. 1516 2/hep.26363" target="_blank" title="It opens in new window">CrossRef
  26. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878鈥?887
  27. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype-1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the聽COSMOS randomised study. Lancet. 2014;384:1756鈥?765
  28. Osinusi, A, Meissner, EG, Lee, YJ (2013) Sofosbuvir and ribavirin for hepatitis C genotype-1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA 310: pp. 804-811 2013.109309" target="_blank" title="It opens in new window">CrossRef
  29. Gane, EJ, Stedman, CA, Hyland, RH (2014) Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype-1 infection. Gastroenterology 146: pp. 736-743 2013.11.007" target="_blank" title="It opens in new window">CrossRef
  30. Jacobson, IM, Gordon, SC, Kowdley, KV (2013) Sofosbuvir for hepatitis C genotype-2 or 3 in patients without treatment options. N Engl J Med 368: pp. 1867-1877 214854" target="_blank" title="It opens in new window">CrossRef
  31. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370(21):1993鈥?001
  32. Sulkowski, MS, Naggie, S, Lalezari, J (2014) Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA 312: pp. 353-361 2014.7734" target="_blank" title="It opens in new window">CrossRef
  33. Kohli A, Sims Z, Nelson A, et al. Combination Oral, Hepatitis C Antiviral Therapy for 6 or 12 Weeks: Final Results of the SYNERGY Trial. / 21st Conference on Retroviruses and Opportunistic Infections 2014, March 3鈥?, Abstract 27LB
  34. Lo, RV, Teal, V, Localio, AR (2011) Relationship between adherence to hepatitis C virus therapy and virologic outcomes: a cohort study. Ann Intern Med 155: pp. 353 26/0003-4819-155-9-201111010-00016" target="_blank" title="It opens in new window">CrossRef
  35. Gane EJ, Hyland RH, An D, et al. Sofosbuvir/Ledipasvir fixed dose combination is safe and effective in difficult-to-treat populations including genotype-3 patients, decompensated genotype-1 patients, and genotype-1 patients with prior Sofosbuvir treatment experience. / 49th European Association for the Study of the Liver International Liver Congress (EASL) 2014, London. April 9鈥?3, Abstract O6
  36. Osinusi A, Marti M, Townsend K, et al. Retreatment of relapsers to Sofosbuvir/ribavirin with sofosbuvir/ledipasvir: complete and rapid virologic suppression by week 4. / 49th European Association for the Study of the Liver International Liver Congress (EASL) 2014, London. April 9鈥?3, Abstract O11
  37. Esteban R, Nyberg L, Lalezari J, et al. Successful retreatment with Sofosbuvir-containing regimens for HCV genotype-2 or 3 infected patients who failed prior Sofosbuvir plus ribavirin therapy. / 49 / th / European Association for the Study of the Liver International Liver Congress (EASL) 2014, London. April 9鈥?3, Abstract O8
  38. Tapper, EB, Afdhal, NH (2013) Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype-3. J Viral Hepat 20: pp. 669-677 2168" target="_blank" title="It opens in new window">CrossRef
  39. Gane E. ELECTRON-2: Ledipasvir plus Sofosbuvir fixed-dose combination. / 49th European Association for the Study of the Liver International Liver Congress (EASL) 2014, London. April 9鈥?3, Abstract O6
  40. Everson GT, Tran TT, Towner WJ, et al. Safety and efficacy of treatment with the interferon-free, ribavirin-free combination of Sofosbuvir + GS-5816 for 12 weeks in treatment-naive patients with genotype-1-6 HCV infection. / 49th European Association for the Study of the Liver International Liver Congress (EASL) 2014, London. April 9鈥?3, Abstract O111
  41. Osinusi A, et al. Use of Sofosbuvir/Ledipasvir fixed dose combination for treatment of HCV genotype-1 in patients coinfected with HIV. / 49th European Association for the Study of the Liver International Liver Congress (EASL) 2014, London. April 9鈥?3, Oral Abstract O14
  42. Nair, SP (2012) Management of hepatitis C virus infection in liver transplant recipients. Gastroenterol Hepatol 8: pp. 56-59
  43. Forns X. Initial Evaluation of the Sofosbuvir Compassionate Use Program for Patients With Severe Recurrent HCV Following Liver Transplantation / 64th Annual Meeting of the American Association for the Study of Liver Diseases 2013. Washington, DC, November 1鈥?
  
• 刊物主题：Hepatology; Colorectal Surgery; Surgery;
• 出版者：Springer India
• ISSN：1936-0541

文摘

Chronic hepatitis C is a leading cause of liver-related morbidity and mortality worldwide. If untreated, chronic hepatitis C can progress to advanced liver fibrosis, cirrhosis, liver failure, hepatocellular carcinoma and death. Until recently, treatment of hepatitis C predominantly constituted an immunomodulatory agent, peg-interferon-alfa and ribavirin. In 2011, the first class of directly acting antiviral agents, HCV NS3/4A serine protease inhibitors, was added to peg-interferon-alfa and ribavirin with increased efficacy. In the past year, an NS5B inhibitor, sofosbuvir, has emerged as a potent agent with pangenotypic efficacy, resulting in the first interferon-free regimen for the treatment of hepatitis C. This review summarizes the data that resulted in regulatory approval of sofosbuvir and highlights the future of hepatitis C therapy with sofosbuvir as the backbone of a highly effective antiviral regimen.